Overview

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Status:
RECRUITING

Trial end date:
2027-04-19

Target enrollment:

Participant gender:

Summary

The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.

Phase:

PHASE3

Details

Lead Sponsor:

AstraZeneca

Treatments:

apatinib
Docetaxel
Irinotecan
Paclitaxel
trifluridine tipiracil drug combination